# Nuvalent

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuvalent

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.nuvalent.com
- Total disclosed funding: $185M
- Latest round: Series B (May 11, 2021)
- Investors on record: 12

## About

Based in Massachusetts, US, and founded in 2017, Nuvalent, Inc., is a biotechnology company that develops therapies for clinically proven kinase targets in cancer and designs innovative molecular structures that enable therapies to treat tumors. The company was founded by James R. Porter and Matthew Shair. In July 2021, Nuvalent went public with ticker symbol NUVL and has raised USD 165.75 million in an IPO, selling 9.75 million shares at USD 17 per share on the Nasdaq. The company currently has 31 employees.

Nuvalent, Inc. provides medicines with the potential to achieve deep and durable responses with minimal side effects for patients with cancer. The company has 2 programs; NUV-520 which is a novel ROS1-selective inhibitor and potential therapy for patients with advanced NSCLC (Non-small cell lung cancer) driven by a ROS1 fusion. And NUV-655, a novel ALK-selective inhibitor created for patients with advanced NSCLC tumors driven by an ALK fusion.

Nuvalent plans to begin clinical trials in patients with ROS1-positive non-small cell lung cancer and other advanced solid tumors in the second half of 2021. The firm is also exploring a pipeline of programs with a focus on addressing the limitations of existing therapies for other clinically proven kinase targets in oncology.

## Funding rounds

- Series B, May 11, 2021, $135M — Bain Capital, Venrock, Wellington Management, Viking Global Investors, Fidelity Investments, Driehaus Capital Management, Deerfield Management, Boxer Capital, Fairmount Funds Management, Janus Henderson Investors, Logos Capital, Avoro Capital Advisors
- Series A, Jan 27, 2021, $50M — Deerfield Management

## Investors

- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A, Series B
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series B
- Venrock (https://capitalatlas.ai/funds/venrock) — Series B
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Driehaus Capital Management (https://capitalatlas.ai/funds/driehaus-capital-management) — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B
- Fairmount Funds Management — Series B
- Janus Henderson Investors — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B
- Avoro Capital Advisors — Series B